Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma.
BCMA
CAR-T
Multiple myeloma
Journal
Journal of hematology & oncology
ISSN: 1756-8722
Titre abrégé: J Hematol Oncol
Pays: England
ID NLM: 101468937
Informations de publication
Date de publication:
03 12 2020
03 12 2020
Historique:
received:
11
10
2020
accepted:
17
11
2020
entrez:
4
12
2020
pubmed:
5
12
2020
medline:
8
6
2021
Statut:
epublish
Résumé
B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR)-T-cell therapy is an emerging treatment option for multiple myeloma. The aim of this systematic review and meta-analysis was to determine its safety and clinical activity and to identify factors influencing these outcomes. We performed a database search using the terms "BCMA," "CAR," and "multiple myeloma" for clinical studies published between 01/01/2015 and 01/01/2020. The methodology is further detailed in PROSPERO (CRD42020125332). Twenty-three different CAR-T-cell products have been used so far in 640 patients. Cytokine release syndrome was observed in 80.3% (69.0-88.2); 10.5% (6.8-16.0) had neurotoxicity. A higher neurotoxicity rate was reported in studies that included more heavily pretreated patients: 19.1% (13.3-26.7; I Although considerable toxicity was observed, BCMA-targeted CAR-T-cell therapy is highly efficacious even in advanced multiple myeloma. Subgroup analysis confirmed the anticipated inter-study heterogeneity and identified potential factors contributing to safety and efficacy. The results of this meta-analysis may assist the future design of CAR-T-cell studies and lead to optimized BCMA CAR-T-cell products.
Sections du résumé
BACKGROUND
B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR)-T-cell therapy is an emerging treatment option for multiple myeloma. The aim of this systematic review and meta-analysis was to determine its safety and clinical activity and to identify factors influencing these outcomes.
METHODS
We performed a database search using the terms "BCMA," "CAR," and "multiple myeloma" for clinical studies published between 01/01/2015 and 01/01/2020. The methodology is further detailed in PROSPERO (CRD42020125332).
RESULTS
Twenty-three different CAR-T-cell products have been used so far in 640 patients. Cytokine release syndrome was observed in 80.3% (69.0-88.2); 10.5% (6.8-16.0) had neurotoxicity. A higher neurotoxicity rate was reported in studies that included more heavily pretreated patients: 19.1% (13.3-26.7; I
CONCLUSIONS
Although considerable toxicity was observed, BCMA-targeted CAR-T-cell therapy is highly efficacious even in advanced multiple myeloma. Subgroup analysis confirmed the anticipated inter-study heterogeneity and identified potential factors contributing to safety and efficacy. The results of this meta-analysis may assist the future design of CAR-T-cell studies and lead to optimized BCMA CAR-T-cell products.
Identifiants
pubmed: 33272302
doi: 10.1186/s13045-020-01001-1
pii: 10.1186/s13045-020-01001-1
pmc: PMC7713173
doi:
Substances chimiques
B-Cell Maturation Antigen
0
Receptors, Chimeric Antigen
0
Types de publication
Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
164Références
J Hematol Oncol. 2020 Sep 17;13(1):125
pubmed: 32943087
Lancet. 2015 May 30;385(9983):2197-208
pubmed: 25540889
N Engl J Med. 2014 Oct 16;371(16):1507-17
pubmed: 25317870
Mol Ther Oncolytics. 2019 Aug 28;15:60-68
pubmed: 31650026
Clin Lymphoma Myeloma Leuk. 2018 Sep;18(9):611-627
pubmed: 30001985
Eur J Haematol. 2018 Apr 20;:
pubmed: 29676004
J Clin Invest. 2019 Mar 21;129(6):2210-2221
pubmed: 30896447
Proc Natl Acad Sci U S A. 2019 May 7;116(19):9543-9551
pubmed: 30988175
N Engl J Med. 2015 Sep 10;373(11):1040-7
pubmed: 26352815
Eur J Haematol. 2020 Apr;104(4):318-327
pubmed: 31883150
Ann Oncol. 2010 Oct;21 Suppl 7:vii143-50
pubmed: 20943607
Lancet Oncol. 2016 Aug;17(8):e328-e346
pubmed: 27511158
Cancer Discov. 2017 Dec;7(12):1404-1419
pubmed: 29025771
Antibodies (Basel). 2019 Jul 03;8(3):
pubmed: 31544847
J Hematol Oncol. 2019 Nov 21;12(1):120
pubmed: 31752943
J Hematol Oncol. 2018 Oct 22;11(1):128
pubmed: 30348186
Best Pract Res Clin Haematol. 2018 Jun;31(2):147-157
pubmed: 29909915
Front Immunol. 2019 Jul 16;10:1613
pubmed: 31379824
Blood. 2016 Sep 29;128(13):1688-700
pubmed: 27412889
Leukemia. 2020 Apr;34(4):985-1005
pubmed: 32055000
Pharmaceutics. 2020 Feb 24;12(2):
pubmed: 32102267
Nat Commun. 2020 Jan 15;11(1):283
pubmed: 31941907
Cancers (Basel). 2019 Apr 30;11(5):
pubmed: 31052261
EMBO Mol Med. 2017 Sep;9(9):1183-1197
pubmed: 28765140
Front Immunol. 2017 Dec 22;8:1934
pubmed: 29312360
Lancet Haematol. 2019 Oct;6(10):e521-e529
pubmed: 31378662
Nat Med. 2018 May;24(5):563-571
pubmed: 29713085
J Clin Oncol. 2018 Aug 1;36(22):2267-2280
pubmed: 29812997
J Hematol Oncol. 2018 Sep 24;11(1):121
pubmed: 30249264
N Engl J Med. 2019 May 2;380(18):1726-1737
pubmed: 31042825
CA Cancer J Clin. 2014 Nov-Dec;64(6):422-44
pubmed: 25266555
Cancer Discov. 2018 Aug;8(8):958-971
pubmed: 29880584
Leukemia. 2020 Jan;34(1):21-34
pubmed: 31780814
N Engl J Med. 2013 Apr 18;368(16):1509-1518
pubmed: 23527958
Front Immunol. 2018 Aug 10;9:1821
pubmed: 30147690
J Hematol Oncol. 2018 Dec 20;11(1):141
pubmed: 30572922
Am Soc Clin Oncol Educ Book. 2018 May 23;38:e6-e15
pubmed: 30231373
Nature. 2019 Apr;568(7750):112-116
pubmed: 30918399